ATLANTA -- New research presented at ACR Convergence, the American College Rheumatology's annual meeting, reveals that romosozumab, an osteoporosis drug, produces substantial gains in bone mineral ...

Please provide your email address to receive an email when new articles are posted on . Researchers conducted a post-hoc analysis of two phase 3 trials, the Fracture Study in Postmenopausal Women with ...

Romosozumab was not associated with increased cardiovascular risks among patients with osteoporosis when compared with bisphosphonate use. Romosozumab does not appear to significantly increase the ...

Belgium: Researchers have reported that age does not appear to influence how postmenopausal women with osteoporosis respond to romosozumab therapy, based on real-world evidence from a ...

Please provide your email address to receive an email when new articles are posted on . Romosozumab as a first treatment produces ‘substantial gains’ in hip and lumbar spine bone mineral density ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD among postmenopausal women with T2D and osteoporosis. Romosozumab followed by alendronate treatment ...

Romosozumab leads to a greater increase in bone mineral density (BMD) than teriparatide in postmenopausal women, with lower discontinuation rates and fewer cardiovascular events. Romosozumab and ...

Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME). These data ...

Conclusions In postmenopausal women with osteoporosis, romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months ...

Peter L. Salgo, MD: Based on all this, I know you said there were data. There were trials. I’ve gotten this written down. I’m not making this up. There’s the FRAME study, and there’s the ARCH study.

The US Food and Drug Administration (FDA) has rejected the osteoporosis drug romosozumab (Amgen/UCB Pharma), a decision that was widely expected when the companies reported a higher rate of serious ...